Heart attack

February 9, 2019

Ribonucleic acid-based therapy for cardiac diseases: MDRL (Mitochondrial dynamic related lncRNA) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via up-regulation of its target gene, 9/February/2019, 6.21 am

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
February 6, 2019

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]
February 2, 2019

Molecular therapy for safeguarding your heart against cardiac dysfunction: Sofalcone, a gastrointestinal medication,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 2/February/2019, 5.44 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]
January 31, 2019

Seladelpar (MBX8025/RWJ800025)-based therapy for Cardiac repair and myocardial infarction: Seladelpar (MBX8025/RWJ800025) increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 31/January/2019, 11.14 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]